Hologic, Inc. (HOLX) Expected to Announce Quarterly Sales of $800.84 Million

Brokerages expect Hologic, Inc. (NASDAQ:HOLX) to post $800.84 million in sales for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Hologic’s earnings. The highest sales estimate is $804.70 million and the lowest is $791.50 million. Hologic reported sales of $806.10 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 0.7%. The firm is scheduled to announce its next earnings results on Wednesday, August 1st.

On average, analysts expect that Hologic will report full year sales of $3.20 billion for the current year, with estimates ranging from $3.18 billion to $3.24 billion. For the next year, analysts expect that the firm will report sales of $3.33 billion per share, with estimates ranging from $3.30 billion to $3.40 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Hologic.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.53 EPS for the quarter, meeting analysts’ consensus estimates of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The company had revenue of $789.30 million during the quarter, compared to analyst estimates of $781.23 million. During the same period last year, the business earned $0.50 earnings per share. Hologic’s revenue was up 10.3% compared to the same quarter last year.

A number of research firms have recently commented on HOLX. Leerink Swann lowered shares of Hologic from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $48.00 to $41.00 in a research report on Thursday, May 3rd. Stifel Nicolaus lowered their target price on shares of Hologic from $42.00 to $40.00 and set a “hold” rating on the stock in a research note on Thursday, May 3rd. Canaccord Genuity downgraded shares of Hologic from a “buy” rating to a “hold” rating and lowered their target price for the company from $48.00 to $39.00 in a research note on Thursday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 target price (down from $50.00) on shares of Hologic in a research note on Tuesday, May 1st. Finally, BidaskClub raised shares of Hologic from a “sell” rating to a “hold” rating in a research note on Friday, April 27th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company. Hologic currently has an average rating of “Hold” and an average price target of $44.87.

In related news, SVP Allison P. Bebo sold 7,000 shares of Hologic stock in a transaction on Friday, March 16th. The shares were sold at an average price of $38.75, for a total value of $271,250.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Peter J. Valenti III sold 10,107 shares of Hologic stock in a transaction on Tuesday, May 29th. The stock was sold at an average price of $38.52, for a total transaction of $389,321.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,303 shares of company stock worth $1,148,412. 0.88% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Advisers LP increased its stake in shares of Hologic by 28.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,828,311 shares of the medical equipment provider’s stock worth $120,910,000 after buying an additional 620,761 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Hologic by 15.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,301,792 shares of the medical equipment provider’s stock worth $85,995,000 after buying an additional 301,278 shares during the period. Guggenheim Capital LLC increased its stake in shares of Hologic by 4.7% in the first quarter. Guggenheim Capital LLC now owns 1,739,642 shares of the medical equipment provider’s stock worth $64,993,000 after buying an additional 77,589 shares during the period. Amundi Pioneer Asset Management Inc. increased its stake in shares of Hologic by 818.9% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 1,521,695 shares of the medical equipment provider’s stock worth $56,851,000 after buying an additional 1,356,091 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Hologic by 2.4% in the first quarter. Legal & General Group Plc now owns 1,421,810 shares of the medical equipment provider’s stock worth $53,122,000 after buying an additional 33,131 shares during the period. 93.33% of the stock is currently owned by institutional investors.

Shares of Hologic traded up $1.49, reaching $40.23, during trading hours on Monday, Marketbeat reports. The stock had a trading volume of 4,159,655 shares, compared to its average volume of 2,515,086. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 1.13. Hologic has a 12 month low of $35.10 and a 12 month high of $46.80. The firm has a market capitalization of $10.49 billion, a P/E ratio of 19.67, a price-to-earnings-growth ratio of 1.81 and a beta of 0.86.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply